Company Overview

Update
Headquarters:
Schlieren
Funding:
$22.1M
Categories:
Biotechnology
Description:
GlycoVaxyn is a biotechnology company employing its proprietary glycoprotein technology to develop vaccines for bacterial infections.

Detailed Description

Update

GlycoVaxyn has built a broad portfolio of conjugate vaccines against common severe bacterial infections based on its unique, proprietary invivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoproteins in a simplified biological process that circumvents many of the difficulties involved in current methods. The lead conjugate vaccines in development are directed against Shigella dysenteriae, to prevent serious intestinal infections, and against hospital acquired Staphylococcus aureus. GlycoVaxyn also has active programs against N. meningitidis and Group A Streptococcus. GlycoVaxyn, a spinout of the Swiss Federal Institute of Technology (ETH), is based in Schlieren, near Zurich, Switzerland.

Funding Rounds (2) - $22.1M

Update

Investors (3)

Update
  • E5e00ec4ecc92739b01aeee0458c3b9b

    Sofinnova Partners

    Sofinnova Partners is an independent venture capital firm based in Paris, France. For over 35...
  • 4b8cb82cceb342829beea060f74f8ad3

    Index Ventures

    Index Ventures is a multi-stage international venture capital firm with deep sector expertise...
  • F68c2599dc7b91c6b4ca3eaf3a052c45

    Edmond de Rothschild Venture Capital

    Edmond de Rothschild Venture Capital invests in companies involved in the human health industry.

Offices/Locations (1)

Update
  • GlycoVaxyn AG

    Grabenstrasse 3

    Schlieren, 8952

    CHE